secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch & Lomb Corp (BLCO)
CIK:        0001860742
Form:       8-K
Filed at:   2026-08-06T11:10:22+00:00
Accession:  0000950103-26-011979
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bausch + Lomb appoints four new directors, reaffirms 2026 guidance after Q2 revenue of $1.394B
--------------------------------------------------------------------------------

- Q2 revenue $1.394B, up 9% reported and 8% constant currency vs Q2 2025; broad-based double-digit growth in Surgical and Pharma.
- Cash flow from operations rose to $153M in Q2 from $32M in Q1; adjusted cash flow from operations $161M.
- Full-year 2026 guidance reaffirmed: revenue $5.44B–$5.54B, Adj EBITDA (ex-IPR&D) $1.025B–$1.075B.
- Board adds Thomas Appio (CEO of Bausch Health), Robert Chersi, Laurence Paul, and Barbara Trebbi; four prior directors resigned.
- Resignations not due to disagreement; departing directors receive prorated cash and full RSU vesting; Thomas Ross gets $400K consulting fee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860742/000095010326011979/0000950103-26-011979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860742/000095010326011979/dp251415_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-26-011979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer